In a post-surgery setting, initiate MRD testing to inform critical adjuvant therapy decisions.1
MRD, minimal residual disease.
Important Note: The Guardant Reveal test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant Reveal refers to Guardant Reveal Laboratory Developed Test (LDT). This test has not been cleared or approved by the US FDA.
Home Guardant Infinity™ for HCPs Treatment Selection Monitoring and MRD Assessment Guardant Infinity™ for BioPharma